The estimated Net Worth of Standish Fleming is at least $659 Mille dollars as of 15 February 2006. Standish Fleming owns over 125,000 units of Acorda Therapeutics Inc stock worth over $659,267 and over the last 19 years Standish sold ACOR stock worth over $0.
Standish has made over 1 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Standish bought 125,000 units of ACOR stock worth $750,000 on 15 February 2006.
The largest trade Standish's ever made was buying 125,000 units of Acorda Therapeutics Inc stock on 15 February 2006 worth over $750,000. On average, Standish trades about 125,000 units every 0 days since 2006. As of 15 February 2006 Standish still owns at least 998,889 units of Acorda Therapeutics Inc stock.
You can see the complete history of Standish Fleming stock trades at the bottom of the page.
Standish's mailing address filed with the SEC is C/O ACORDA THERAPEUTICS, INC, 15 SKYLINE DRIVE, HAWTHORNE, NY, 10532.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith e Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: